Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Orphazyme A/S
The Danish group’s pursuit of Timber, and its late-stage congenital ichthyosis therapy, has finally reached a successful conclusion and CEO Christophe Bourdon tells Scrip that the search is on for more innovative assets.
Acer's bank reserves have dwindled down to next to nothing following the failure of its menopause drug, osanetant, in a Phase II trial some six months ago. Enter Zevra, which is getting hold of the company and its just-launched urea cycle disorder drug, Olpruva, in what looks like a bargain.
Pink Sheet analysis finds big jump in the share of novel approvals that received PDUFA extensions, largely driven by clinical and safety data submissions.
The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.
- Large Molecule
- Other Names / Subsidiaries
- Orphazyme US, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.